Zymeworks has filed a patent for masked IL12 fusion proteins, which are designed to treat various diseases, including cancer. The proteins consist of an Fc domain, a masking moiety, and an IL12 polypeptide. The masking moiety is fused to the Fc domain through a linker. GlobalData’s report on Zymeworks gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zymeworks, personalized cancer vaccines was a key innovation area identified from patents. Zymeworks's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Masked il12 fusion protein for treating diseases including cancer
A recently filed patent (Publication Number: US20230122079A1) describes a masked interleukin 12 (IL12) fusion protein. IL12 is a protein that plays a role in the immune system and has potential therapeutic applications in cancer
To know more about GlobalData’s detailed insights on Zymeworks, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
